Axsome Therapeutics, based in New York City, develops therapies for central nervous system disorders, with commercial products Auvelity and Sunosi, and investigational drugs AXS-05 and AXS-07. The company employs 545 staff and went public in November 2015.
Hunter R Murdock sold 6,014 shares of AXSM on 23 June at $100.12 per share, worth a total of $602K. They now own 0 AXSM shares, or a 100% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
